US drug maker Pfizer will release its first-quarter results tomorrow just weeks after the US treasury department blocked its plan to merge with Botox maker Allergan.

The analysts’ current consensus range is $0.52-$0.58 for earnings per share, while the consensus range for revenue is $11.37 billion-$12.91 billion, with an average of $11.99 billion. Back in February, Pfizer posted earnings per share at $0.53, which topped analyst estimates.

Revenue came in at $14.05 billion versus the consensus estimate of $13.56 billion. Global vaccines revenue rose 45 per cent to $1.92 billion, driven by a 102 per cent growth in its pneumonia vaccine, Prevnar 13, in the United States.

Pfizer and Allergan called off a €140 billion merger last month after the Obama administration introduced emergency regulations designed to block such transactions.

Pfizer had planned to shift its tax base to Ireland by merging with the Botox maker. The deal would have allowed Pfizer to avoid US tax bills on more than $128 billion of profits earned overseas.

Investors will most likely seek answers about what Pfizer’s next move will be, following the Allergan merger failure. At the Pfizer agm last week, company executives faced sharp criticism from shareholders in relation to the merger.

Fleetmatics Q1

Meanwhile, Fleetmatics will report first-quarter earnings on Wednesday. The Dublin-based provider of GPS-based fleet management systems is expected to post earnings of $0.19 per share.

Fleetmatics last reported results in February, when it posted earnings of $0.31 for the fourth quarter of 2015.

At the time, the company also announced it had exceeded 700,000 active vehicles under subscription, adding more than 157,000 vehicles in 2015.

The Tallaght-headquartered company, which develops and sells fleet-management software to some 24,000 SMEs, said total revenue for 2015 was $284.8 million, an increase of 23 per cent compared to $231.6 million for 2014.